1-4 of 4
Ioannis Melakopoulos
Close
Sort by
Journal Articles

Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy

Pelagia Melea, Tina Bagratuni, Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Melakopoulos, Efstathios Kastritis, MD, Meletios A. Dimopoulos
Journal: Blood
Blood (2014) 124 (21): 2115.
https://doi.org/10.1182/blood.V124.21.2115.2115
Published: 2014
Journal Articles

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Efstathios Kastritis, Evangelos Terpos, Ioannis Melakopoulos, Pelagia Melea, Despoina Kalapanida, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Marina Iakovaki, Dimitrios Christoulas, Dimitra Gika, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2013) 122 (21): 3196.
https://doi.org/10.1182/blood.V122.21.3196.3196
Published: 2013
Journal Articles

Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.

Meletios Athanasios Dimopoulos, MD, Efstathios Kastritis, MD, Christina Bamia, Ioannis Melakopoulos, MD, Dimitra Gika, Maria Roussou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Aristotle Bamias, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3609.
https://doi.org/10.1182/blood.V110.11.3609.3609
Published: 2007
Journal Articles

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Meletios A. Dimopoulos, MD, Efstathios Kastritis, MD, Lia A. Moulopoulos, MD, Ioannis Melakopoulos, MD, Athanasios Anagnostopoulos, MD, Dimitra Gika, George Bozas, MD, Vassiliki Koutsoukou, MD, Aristotelis Bamias, MD
Journal: Blood
Blood (2005) 106 (11): 637.
https://doi.org/10.1182/blood.V106.11.637.637
Published: 2005